Drug intelligence / Profile preview

miR-3662

Development stage
Preclinical
Lead developer
The Ohio State University
Modality
RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Subcutaneous
01

Overview

miR-3662 is a microRNA located within the chromosome 6q23.3 hematopoietic quantitative trait locus (QTL). It functions as a tumor suppressor in the context of malignant hematopoiesis, particularly acute myeloid leukemia (AML). The microRNA exerts its effect by directly targeting the 3′-UTR of IKBKB (Inhibitor of nuclear factor kappa-B kinase subunit beta), which results in reduced mRNA and protein expression of IKBKB. This inhibition leads to decreased activation and nuclear localization of NF-κB, a key transcription factor in cancer cell survival. Preclinical studies have demonstrated that miR-3662 overexpression reduces cell growth and viability in AML cell lines and primary patient blasts, and significantly decreases tumor size in murine xenograft models.

Other names
microRNA-3662microRNA3662microRNA 3662
02

Targets

Calcium binding protein 39-like mRNA 3'-untranslated regionZEB1 (Zinc finger E-box-binding homeobox 1)

Beyond the preview

Go deeper on miR-3662.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-3662.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call